6 Results for "

Liver failure model

" in MedChemExpress (MCE) Product Catalog:
Products (6)

6 Results for "Liver failure model" in MCE Product Catalog:

4
4 Cited Publications
Cat. No.: HY-42682
CAS No.: 1772-03-8
Synonyms: D-Galactosamine HCl
D(+)-Galactosamine (D-Galactosamine) hydrochloride, which is an established experimental toxin, primarily causes liver injury by the generation of free radicals and depletion of UTP nucleotides. D(+)-Galactosamine hydrochloride intoxication also induces renal dysfunction thus, renal failure is often associated with the end-stage of the liver damage. Lipopolysaccharide/D(+)-Galactosamine-induced acute liver injury is a known animal model of fulminant hepatic failure .
loading...
    loading...
Cat. No.: HY-42682R
CAS No.: 1772-03-8
Synonyms: D-Galactosamine HCl (Standard)
D(+)-Galactosamine (hydrochloride) (Standard) is the analytical standard of D(+)-Galactosamine (hydrochloride). This product is intended for research and analytical applications. D(+)-Galactosamine (D-Galactosamine) hydrochloride, which is an established experimental toxin, primarily causes liver injury by the generation of free radicals and depletion of UTP nucleotides. D(+)-Galactosamine hydrochloride intoxication also induces renal dysfunction thus, renal failure is often associated with the end-stage of the liver damage. Lipopolysaccharide/D(+)-Galactosamine-induced acute liver injury is a known animal model of fulminant hepatic failure .
loading...
    loading...
Cat. No.: HY-177809
Target:  

TNF Receptor

Research Areas:  

Inflammation/Immunology

aptTNF-α sodium is a TNF-α-targeting aptamer that has tissue protective effect and systemic anti-inflammatory effect upon acute tissue injury using the mouse acute lung injury (ALI) and acute liver failure (ALF) models.
loading...
    loading...
Cat. No.: HY-171900
Target:  

Liposome

Research Areas:  

Inflammation/Immunology

Lipid 114 is an ionizable cationic lipid with a pKa of approximately 6.8. Lipid 114 can be used to generate lipid nanoparticles (LNP) to deliver siRNA in vitro as well as in vivo. Lipid 114 LNPs encapsulating siRNA that targets IL-1β can reduce IL-1β expression in macrophages. Lipid 114 LNPs encapsulating siRNA that targets IL-1β also reduces hepatic and renal expression of IL-1β, as well as decreasing hepatic inflammation in mouse model with LPS-induced acute liver failure .
loading...
    loading...
Cat. No.: HY-184736
STAT3/NF-κB-IN-3 is an orally active STAT3/NF-κB inhibitor with anti-inflammatory and antioxidant activities, which specifically blocks the phosphorylation of NF-κB and STAT3 proteins. STAT3/NF-κB-IN-3 downregulates the expression of iNOS and NOX-2 in macrophages, reduces intracellular levels of ROS and MDA, and upregulates the expression of antioxidant genes at the same time. In a mouse model of acute liver failure induced by LPS/D-GalN, STAT3/NF-κB-IN-3 alleviates liver necrosis and inflammatory cell infiltration, and reduces the release of pro-inflammatory cytokines such as IL-6 and IL-12 via the TLR4 pathway. STAT3/NF-κB-IN-3 can be used in studies related to acute liver failure .
loading...
    loading...
Cat. No.: HY-189721
CBI-3 is a BAX inhibitor that covalently modifies BAX and blocks BAX-mediated apoptosis. CBI-3 protects primary rat dorsal root ganglion neurons and human induced pluripotent stem cell-derived motor neurons from apoptosis and spontaneous loss. CBI-3 reduces hepatocyte apoptosis and protects liver histology in an anti-Fas-induced acute liver injury mouse model. CBI-3 exhibits improved metabolic stability in mouse liver microsomes. CBI-3 can be used for research on Fas-induced fulminant hepatic failure and amyotrophic lateral sclerosis .
loading...
    loading...